Open Access

Circulating miR‑15b, Annexin A1, procalcitonin and interleukin‑6 levels differentiate children with metabolically unhealthy obesity from those with metabolically healthy obesity: A case‑control study

  • Authors:
    • Khalid M. Mohany
    • Osamah Al Rugaie
    • Osama Al‑Wutayd
    • Mansour Alsharidah
    • Abdullah Al‑Nafeesah
  • View Affiliations

  • Published online on: April 21, 2022     https://doi.org/10.3892/etm.2022.11330
  • Article Number: 403
  • Copyright: © Mohany et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study assessed serum miR‑15b, Annexin A1, procalcitonin, and interleukin‑6 (IL‑6) levels in children with metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) and compared them to these levels in a non‑obese healthy control group. It also tested the ability of each of these parameters to early differentiate children with MUO from those with MHO. The present study included 620 children [434 males (70%) and 186 females (30%); aged 9‑15 years] divided into the following groups: G1, healthy non‑obese controls (n=200); G2, MHO (n=246); G3, MUO (n=174). Serum miR‑15b, Annexin A1 procalcitonin, IL‑6, and other metabolic parameters levels were measured, and clinical examinations were conducted for all of the children. After testing the normality of the variable, Kruskal‑Wallis one‑way‑ANOVA, and Spearman correlation coefficients were used. The area under the receiver operating characteristic curve (AUC) was determined to test the variable's ability to differentiate MUO from MHO. miR‑15b, procalcitonin, and IL‑6 levels were significantly higher while Annexin A1 levels were significantly lower in G2 and G3 when compared to G1, and in G3 when compared to G2. These levels were positively correlated (Annexin A1 was negatively correlated) with body mass index (BMI) and waist circumference percentiles, and with serum levels of LDL‑cholesterol, glucose, HbA1c, insulin, and C‑reactive protein (CRP) and with the homeostasis model of insulin resistance (HOMA‑IR). The AUC was 0.92, 0.84, 0.82, and 0.67 for miR‑15b, Annexin A1, procalcitonin, and IL‑6, respectively. In conclusion, determination of serum miR‑15b, Annexin A1, and procalcitonin levels could differentiate children with MUO from those with MHO. This may help the early management of these cases and their accompanying complications.

Related Articles

Journal Cover

June-2022
Volume 23 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mohany KM, Al Rugaie O, Al‑Wutayd O, Alsharidah M and Al‑Nafeesah A: Circulating miR‑15b, Annexin A1, procalcitonin and interleukin‑6 levels differentiate children with metabolically unhealthy obesity from those with metabolically healthy obesity: A case‑control study. Exp Ther Med 23: 403, 2022
APA
Mohany, K.M., Al Rugaie, O., Al‑Wutayd, O., Alsharidah, M., & Al‑Nafeesah, A. (2022). Circulating miR‑15b, Annexin A1, procalcitonin and interleukin‑6 levels differentiate children with metabolically unhealthy obesity from those with metabolically healthy obesity: A case‑control study. Experimental and Therapeutic Medicine, 23, 403. https://doi.org/10.3892/etm.2022.11330
MLA
Mohany, K. M., Al Rugaie, O., Al‑Wutayd, O., Alsharidah, M., Al‑Nafeesah, A."Circulating miR‑15b, Annexin A1, procalcitonin and interleukin‑6 levels differentiate children with metabolically unhealthy obesity from those with metabolically healthy obesity: A case‑control study". Experimental and Therapeutic Medicine 23.6 (2022): 403.
Chicago
Mohany, K. M., Al Rugaie, O., Al‑Wutayd, O., Alsharidah, M., Al‑Nafeesah, A."Circulating miR‑15b, Annexin A1, procalcitonin and interleukin‑6 levels differentiate children with metabolically unhealthy obesity from those with metabolically healthy obesity: A case‑control study". Experimental and Therapeutic Medicine 23, no. 6 (2022): 403. https://doi.org/10.3892/etm.2022.11330